Advertisement I-Flow Launches Full Line Of ON-Q SilverDressings - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

I-Flow Launches Full Line Of ON-Q SilverDressings

Dressings contain ionic silver, effective in killing or inhibiting the growth of a wide range of microorganisms

I-Flow, through its wholly-owned subsidiary AcryMed, has announced the availability of its family of four conveniently sized ON-Q SilverDressings. These thin film dressings contain ionic silver that is 99.99% effective in killing or inhibiting the growth of a wide range of microorganisms including MRSA1, for up to 7 days. This added layer of antimicrobial protection is said to reduce the risk of infection, which may help facilities avoid incremental treatment costs.

In addition to surgical site care and incisional catheter applications, ON-Q SilverDressings are also recommended for any clinical application where the risk of infection is a concern, including catheter securements for peripheral IV, central lines, epidural and PICC/midline. The dressings create a physical barrier that helps prevent microbes from entering the site and also have an ionic silver barrier that kills or inhibits the growth of microbes on the dressing, potentially shielding the wound site from infection.

The ON-Q SilverDressings have a moisture vapor transmission rate (MVTR) well above the standard dressings. The dressings are available in the following sizes: 2 in. X 3 in., 4 in. X 4.5 in., 4 in. X 8 in. and 8 in. X 8 in.

Donald Earhart, chairman, president and CEO of I-Flow, said: “We are pleased to announce the availability of our ON-Q SilverDressings, because we believe the ‘one-two punch’ of physical and antimicrobial barriers against infection can protect both patients and hospitals.

“Our new innovative dressings with ionic silver technology may deliver double protection against infection to the patient and the spread of infection to others. This can potentially lead to better patient outcomes and potentially help clinicians and hospitals prevent certain costly HAC that are no longer reimbursable by CMS and some other insurance companies.”